Eisai’s Aricept Seen Driving 35 Percent Profit Increase For FY09
This article was originally published in PharmAsia News
Executive SummaryEisai expects a profit increase of about 35 percent in the fiscal year just beginning, with much of the increase due to its Aricept (donepezil) to treat Alzheimer's disease. Another major Eisai sales generator is expected to be its acquisition of U.S.-based MGI Pharma and its cancer drugs. Eisai can expect a large increase in expenses for research and development, however, because of the MGI purchase. In all, Eisai's net profit for the fiscal year that began April 1 is expected to increase by 35 percent. (Click here for more - a subscription may be required
You may also be interested in...
The Chinese government's plan to reduce tariffs it imposed on a slew of US exports is expected to have minimal impact on the overall medtech industry. See what Ralph Ives, AdvaMed's executive VP for global strategy, said about it here.